Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens

AIDS. 2012 Sep 10;26(14):1837-40. doi: 10.1097/QAD.0b013e32835705dd.

Abstract

Thirty-nine HIV-1-infected patients treated for 156 weeks with a new nucleoside analogue-sparing regimen [raltegravir, etravirine and maraviroc (REM) or raltegravir, etravirine and darunavir/ritonavir (RED)] showed a uniform increase in fasting glucose levels and a uniform decrease in insulin secretory capacity. Diabetes mellitus occurred in one RED-treated and four REM-treated patients. A worsening glucose tolerance was observed in highly treatment-experienced HIV-infected patients receiving effective antiretroviral therapy after virological failure.

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Blood Glucose / drug effects*
  • Cyclohexanes / pharmacology
  • Darunavir
  • Fasting
  • Glucose Tolerance Test
  • HIV Protease Inhibitors / pharmacology
  • HIV Seropositivity / blood*
  • HIV Seropositivity / drug therapy
  • HIV-1 / drug effects*
  • Humans
  • Insulin / blood*
  • Insulin Resistance*
  • Maraviroc
  • Nitriles
  • Pyridazines / pharmacology
  • Pyrimidines
  • Pyrrolidinones / pharmacology
  • Raltegravir Potassium
  • Ritonavir / pharmacology
  • Sulfonamides / pharmacology
  • Treatment Outcome
  • Triazoles / pharmacology
  • Viral Load

Substances

  • Anti-HIV Agents
  • Blood Glucose
  • Cyclohexanes
  • HIV Protease Inhibitors
  • Insulin
  • Nitriles
  • Pyridazines
  • Pyrimidines
  • Pyrrolidinones
  • Sulfonamides
  • Triazoles
  • etravirine
  • Raltegravir Potassium
  • Maraviroc
  • Ritonavir
  • Darunavir